Shares ofÂ Biogen (NASDAQ:BIIB) hardly moved following the release of second-quarter earnings results that beat Wall Street's expectations on the top and bottom lines.Despite that outperformance, the stock was close to flat in mid-afternoon trading Wednesday, down 0.3% as of 2:15 p.m. EDT, because investors aren't expecting double-digit-percentage earnings growth to continue much longer.